ARCHIMED Acquires WiQo S.p.A.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ARCHIMED Acquires Irrimax Corporation

August 28, 2024

Medical Devices

ARCHIMED, a healthcare-focused private equity firm, has acquired Irrimax Corporation, the Lawrenceville, Georgia-based developer of the Irrisept antimicrobial wound lavage system, through its MED Platform II fund. The partnership aims to scale Irrimax's product range, expand its market presence and accelerate global commercial reach; financial terms were not disclosed.

WiQo (via WiQo US) Acquires Love Beauty Pro & Medical to Expand U.S. Presence

March 25, 2024

Healthcare Services

Italian aesthetic-medicine company WiQo (through its newly formed WiQo US, Inc.), backed by healthcare private equity firm ARCHIMED, has acquired Boston-based Love Beauty Pro & Medical, the long-time U.S. distributor and training partner for WiQo's PRX Derm Perfexion. The deal brings distribution, sales and clinical training capabilities in-house to accelerate WiQo's U.S. expansion and deepen local provider relationships.

ARCHIMED Acquires Majority Stake in Cardioline

November 17, 2021

Medical Devices

Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Xpress Biologics

October 5, 2021

Biotechnology

ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.